Early outcomes in adults hospitalized with severe SARS-CoV-2 infection receiving tocilizumab

• Published in: Medicina clinica Vol. 158; no. 11; p. 509
• Main Authors: Sánchez-Montalvá, Adrián, Sellarés-Nadal, Júlia, Espinosa-Pereiro, Juan, Fernández-Hidalgo, Nuria, Pérez-Hoyos, Santiago, Salvador, Fernando, Durà, Xavier, Miarons, Marta, Antón, Andrés, Eremiev-Eremiev, Simeón, Sempere-González, Abiu, Monforte-Pallarés, Arnau, Bosch-Nicolau, Pau, Augustin, Salvador, Sampol, Júlia, Guillén-Del-Castillo, Alfredo, Almirante, Benito
• Format: Journal Article
• Language: English
• Published: Spain 10.06.2022
• Subjects: Adult; Antibodies, Monoclonal, Humanized; Cohort Studies; COVID-19 Drug Treatment; Female; Humans; Male; Middle Aged; Respiratory Distress Syndrome - drug therapy; Respiratory Distress Syndrome - etiology; Respiratory Insufficiency - etiology; Respiratory Insufficiency - therapy; SARS-CoV-2; Treatment Outcome; COVID-19; Viral pneumonia; IL6; SARS-CoV-2; COVID19; Tocilizumab; Inmunomodulación; Immonomodulation; Neumonía viral
• ISSN: 1578-8989
• DOI: 10.1016/j.medcli.2021.06.012

Modulation of the immune system to prevent lung injury is being widely used against the new coronavirus disease (COVID-19). The primary endpoint was mortality at 7 days after tocilizumab administration. Secondary endpoints were admission to the intensive care unit, development of ARDS and respiratory insufficiency among others. We report the preliminary results from the Vall d'Hebron cohort study at Vall d'Hebron University Hospital, in Barcelona (Spain), including all consecutive patients who had a confirmed SARS-CoV-2 infection and who were treated with tocilizumab until March 25th. 82 patients with COVID-19 received at least one dose of tocilizumab. The mean (± SD) age was 59.1 (19.8) years, 63% were male, 22% were of non-Spanish ancestry, and the median (IQR) age-adjusted Charlson index at baseline was 3 (1-4) points. Respiratory failure and ARDS developed in 62 (75.6%) and 45 (54.9%) patients, respectively. Median time from symptom onset to ARDS development was 8 (5-11) days. Mortality at 7 days was 26.8%. Hazard ratio for mortality was 3.3; 95% CI, 1.3-8.5 (age-adjusted hazard ratio for mortality 2.1; 95% CI, 0.8-5.8) if tocilizumab was administered after the onset of ARDS. Early administration of tocilizumab in patients needing oxygen supplementation may be critical to patient recovery. Our preliminary data could inform bedside decisions until more data regarding the precise timing in of initiation of the treatment with tocilizumab.